Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVONEST vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Emergency contraception (FDA-approved),Contraception (as a progestin-only pill or in combination with estrogen),Off-label: treatment of menorrhagia, endometriosis, and as a component of hormone replacement therapy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
ALYACEN 777 is a fictional drug. No standard dosing data available.
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4; undergoes reduction and conjugation; excreted in urine and feces.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Levonorgestrel is extensively bound to sex hormone-binding globulin (SHBG) and albumin; approximately 97-99% bound, with the free fraction being pharmacologically active.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Apparent volume of distribution is about 1.8 L/kg, indicating extensive distribution into tissues beyond plasma water.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral bioavailability is approximately 100% due to minimal first-pass metabolism; levonorgestrel is completely absorbed after oral administration.
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dosage adjustment required for any degree of renal impairment.
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no specific dose adjustment available; use with caution.
No data available for fictional drug ALYACEN 777.
Weight ≥ 75 kg: single dose of levonorgestrel 1.5 mg orally. Weight < 75 kg: single dose of 1.5 mg is also used, but efficacy may be reduced; consider alternative methods.
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women; no specific dose adjustment established for elderly.
No data available for fictional drug ALYACEN 777.
None.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Do not use as regular contraceptive if multiple doses are taken in one cycle,Ectopic pregnancy risk reduced but not eliminated,Menstrual irregularities,Rare cases of hepatic adenoma or thromboembolic events,Use with caution in patients with severe hepatic impairment or malabsorption syndromes
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy,Hypersensitivity to levonorgestrel or any component
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No clinically significant food interactions. Levonest releases levonorgestrel locally in the uterus, and systemic absorption is minimal. No dietary restrictions required.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epidemiologic data. Second/third trimester: No known adverse fetal effects from occasional use; no evidence of fetotoxicity or teratogenicity from clinical studies. However, as a progestin-only contraceptive, it is not indicated during pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Levonorgestrel is excreted into breast milk in small amounts (estimated infant dose <0.1% of maternal dose). M/P ratio not established. No adverse effects reported in breastfed infants with short-term use. The WHO considers it compatible with breastfeeding. Caution with prolonged use may reduce milk supply.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dosing adjustments are applicable as LEVONEST is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy do not require dose modifications because the drug should not be used during pregnancy.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Levonest (levonorgestrel-releasing intrauterine system) provides effective contraception for up to 5 years. It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. May reduce menstrual bleeding and dysmenorrhea. Expulsion risk is highest in first year, especially right after insertion. Check strings after each period. Contraindicated in acute pelvic inflammatory disease, postpartum endometritis, infected abortion, or untreated cervical infection.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Levonest is a small T-shaped device placed in your uterus that releases a hormone to prevent pregnancy for up to 5 years.,You may have irregular bleeding or spotting for the first 3-6 months, which typically decreases over time.,Check the strings at the end of your period each month to ensure the device is in place.,Do not use Levonest if you think you might be pregnant, have a current pelvic infection, or have certain uterine abnormalities.,Most women can use Levonest safely; serious complications are rare but include perforation, expulsion, and infection.,Seek medical attention if you experience severe abdominal pain, fever, heavy bleeding, or missing strings.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVONEST vs ALYACEN 777, answered by our medical review team.
LEVONEST is a Oral Contraceptive that works by Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVONEST and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVONEST is: One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVONEST and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVONEST is classified as Category C. LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epi. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.